Michael M. Kaminski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael M. Kaminski has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Alexander J. Schubert
Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
3 shared publications Robert Greensmith
Max Delbrück Center for Molecular Medicine in the Helmholtz Association
3 shared publications- Sarah Wendlinger
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany
3 shared publications - Verena Klämbt
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Berlin, Germany
3 shared publications Xiao Tan
Harvard Medical School
3 shared publications- Amr Al-Shebel
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany
2 shared publications
Latest Publications
- Open Access
Base Editing as a Therapeutic Strategy for Autosomal Dominant Tubulointerstitial Kidney Disease caused by Pathogenic UMOD Variants
Autosomal dominant tubulointerstitial kidney disease caused by pathogenic UMOD variants (ADTKD- UMOD ) is an untreatable monogenic kidney disease in which misfolded uromodulin is retained in the endoplasmic reticulum and exerts a toxic gain-of-function effect. Here we systematically evaluate the full spectrum of base editing strategies targeting the UMOD locus. Base editors corrected a representative missense patient variant, p.Cys170Tyr, with A-to-G conversion efficiencies of up to 83.4%, restoring uromodulin trafficking to the plasma membrane in cell lines and in human 3D kidney tubuloids. Mutation-agnostic inactivation was achieved by four routes: premature stop codon introduction, splice-site disruption, allele-specific stop codon introduction and promoter attenuation. Maximum on-target efficiencies ranged from 44.1% to 71.9%, providing a strategy set applicable across the UMOD allelic spectrum. Endogenous UMOD expression is rarely recapitulated in human cell models, leaving strategies that act on the endogenous gene difficult to assess in patient cells. We therefore established CRISPR activation (CRISPRa) of the endogenous UMOD promoter and confirmed its ability to upregulate UMOD expression in human urine-derived cells. This approach further enabled quantification of endogenous UMOD transcript reduction following base editing in HEK293 cells. These results establish base editing as a versatile approach for ADTKD- UMOD and provide a primary human system for testing interventions targeting endogenous UMOD expression, from nucleic acid-based silencing to small molecules.
Open AccessBase Editing as a Therapeutic Strategy for Autosomal Dominant Tubulointerstitial Kidney Disease caused by Pathogenic UMOD Variants
Autosomal dominant tubulointerstitial kidney disease caused by pathogenic UMOD variants (ADTKD- UMOD ) is an untreatable monogenic kidney disease in which misfolded uromodulin is retained in the endoplasmic reticulum and exerts a toxic gain-of-function effect. Here we systematically evaluate the full spectrum of base editing strategies targeting the UMOD locus. Base editors corrected a representative missense patient variant, p.Cys170Tyr, with A-to-G conversion efficiencies of up to 83.4%, restoring uromodulin trafficking to the plasma membrane in cell lines and in human 3D kidney tubuloids. Mutation-agnostic inactivation was achieved by four routes: premature stop codon introduction, splice-site disruption, allele-specific stop codon introduction and promoter attenuation. Maximum on-target efficiencies ranged from 44.1% to 71.9%, providing a strategy set applicable across the UMOD allelic spectrum. Endogenous UMOD expression is rarely recapitulated in human cell models, leaving strategies that act on the endogenous gene difficult to assess in patient cells. We therefore established CRISPR activation (CRISPRa) of the endogenous UMOD promoter and confirmed its ability to upregulate UMOD expression in human urine-derived cells. This approach further enabled quantification of endogenous UMOD transcript reduction following base editing in HEK293 cells. These results establish base editing as a versatile approach for ADTKD- UMOD and provide a primary human system for testing interventions targeting endogenous UMOD expression, from nucleic acid-based silencing to small molecules.
- Open Access
- 25 June 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (7) , 5970-5982
CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping
Pharmacogenetic testing enables personalized drug dosing by accounting for genetic variation in drug metabolism. Although there is increasing evidence that genetically guided dosing improves therapeutic efficacy and reduces adverse effects, clinical implementation remains limited as genotyping methods suffer from slow turnaround times and are not optimized for point-of-care use. Here, we present a rapid, multiplexed CRISPR-based assay for genotyping the key CYP2C19 polymorphisms *2, *3, and *17. These variants can alter enzyme activity, impacting the metabolism of drugs such as clopidogrel and mavacamten. Our assay combines isothermal amplification with a dual guide RNA detection strategy, where LwaCas13a selectively detects mutant alleles and LbaCas12a identifies wild-type alleles. In a validation study of 110 participants, the assay showed high concordance with Sanger sequencing, the current gold standard, with variant-specific accuracies of 97.3% (*2), 100% (*3), and 99.1% (*17), demonstrating robust performance across a diverse clinical cohort. The workflow supports both column-based DNA extraction and a simplified, crude extraction protocol. Genotyping results are obtained through either fluorescence detection or multi-analyte lateral-flow readouts, allowing visual interpretation of genotypes with minimal equipment. In conclusion, our findings show that CRISPR-based genotyping can deliver accurate CYP2C19 pharmacogenetic testing, facilitating broader adoption of genotype-guided drug dosing. Furthermore, the programmability of CRISPR-Cas systems enables adaptation to other pharmacogenetic targets relevant to drug metabolism.
- 25 June 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (7) , 5970-5982
Open AccessCRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping
Pharmacogenetic testing enables personalized drug dosing by accounting for genetic variation in drug metabolism. Although there is increasing evidence that genetically guided dosing improves therapeutic efficacy and reduces adverse effects, clinical implementation remains limited as genotyping methods suffer from slow turnaround times and are not optimized for point-of-care use. Here, we present a rapid, multiplexed CRISPR-based assay for genotyping the key CYP2C19 polymorphisms *2, *3, and *17. These variants can alter enzyme activity, impacting the metabolism of drugs such as clopidogrel and mavacamten. Our assay combines isothermal amplification with a dual guide RNA detection strategy, where LwaCas13a selectively detects mutant alleles and LbaCas12a identifies wild-type alleles. In a validation study of 110 participants, the assay showed high concordance with Sanger sequencing, the current gold standard, with variant-specific accuracies of 97.3% (*2), 100% (*3), and 99.1% (*17), demonstrating robust performance across a diverse clinical cohort. The workflow supports both column-based DNA extraction and a simplified, crude extraction protocol. Genotyping results are obtained through either fluorescence detection or multi-analyte lateral-flow readouts, allowing visual interpretation of genotypes with minimal equipment. In conclusion, our findings show that CRISPR-based genotyping can deliver accurate CYP2C19 pharmacogenetic testing, facilitating broader adoption of genotype-guided drug dosing. Furthermore, the programmability of CRISPR-Cas systems enables adaptation to other pharmacogenetic targets relevant to drug metabolism.
- 15 May 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (6) , 3152-3154
Cytosine base editing achieves robust lipoprotein(a) reduction while preserving genomic integrity
- 15 May 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (6) , 3152-3154
Cytosine base editing achieves robust lipoprotein(a) reduction while preserving genomic integrity
- Open Access
Kidney-specific Wdr72 deletion leads to incomplete distal renal tubular acidosis through impaired V-ATPase B1 subunit localization
Background: Distal renal tubular acidosis (dRTA) is a rare kidney disorder characterized by impaired urinary acidification due to defective proton secretion in type A intercalated cells of the collecting duct. Recently, pathogenic variants in the human gene encoding the WD Repeat Domain 72 protein ( WDR72 ) have been reported in patients with dRTA, yet the physiological role of WDR72 in the kidney remains unknown. Methods: To elucidate the renal function of Wdr72, we generated a kidney-specific knockout mouse model ( Wdr72 fl/fl ;Pax8-Cre + ) and assessed acid–base homeostasis under baseline, acute, and chronic acid loading. Results: Wdr72 fl/fl ;Pax8-Cre + mice displayed persistently elevated urinary pH, reduced titratable acid and net acid excretion under basal and acid-loaded conditions, consistent with incomplete dRTA. While the systemic pH remained unchanged compared to controls under standard diet, chronic acid load led to mild hyperchloremic, hypokalemic metabolic acidosis. Notably, urinary NH₄⁺ excretion was increased upon acid loading accompanied by upregulation of key ammoniagenesis enzymes, which was detected even under basal conditions, consistent with a compensatory activation of proximal tubular acid excretion pathways. The total and apical abundance of the V-ATPase B1 subunit decreased markedly within the kidney, despite unchanged transcript levels, suggesting a defect in V-ATPase trafficking or assembly. In addition, morphometric analyses revealed an increased proportion of smaller type A intercalating cells that failed to expand upon acid loading, indicating defective adaptive plasticity. Conclusions: Kidney-specific Wdr72 deletion impairs distal urinary acidification through reduced V-ATPase abundance and apical targeting, altered intercalated cell morphology, and limited adaptive remodeling, resulting in incomplete dRTA. Upregulation of renal ammoniagenesis partially compensates the acidification defect. These findings highlight WDR72 as a key regulator of distal nephron acid–base homeostasis and offer mechanistic insight into WDR72-associated dRTA.
Open AccessKidney-specific Wdr72 deletion leads to incomplete distal renal tubular acidosis through impaired V-ATPase B1 subunit localization
Background: Distal renal tubular acidosis (dRTA) is a rare kidney disorder characterized by impaired urinary acidification due to defective proton secretion in type A intercalated cells of the collecting duct. Recently, pathogenic variants in the human gene encoding the WD Repeat Domain 72 protein ( WDR72 ) have been reported in patients with dRTA, yet the physiological role of WDR72 in the kidney remains unknown. Methods: To elucidate the renal function of Wdr72, we generated a kidney-specific knockout mouse model ( Wdr72 fl/fl ;Pax8-Cre + ) and assessed acid–base homeostasis under baseline, acute, and chronic acid loading. Results: Wdr72 fl/fl ;Pax8-Cre + mice displayed persistently elevated urinary pH, reduced titratable acid and net acid excretion under basal and acid-loaded conditions, consistent with incomplete dRTA. While the systemic pH remained unchanged compared to controls under standard diet, chronic acid load led to mild hyperchloremic, hypokalemic metabolic acidosis. Notably, urinary NH₄⁺ excretion was increased upon acid loading accompanied by upregulation of key ammoniagenesis enzymes, which was detected even under basal conditions, consistent with a compensatory activation of proximal tubular acid excretion pathways. The total and apical abundance of the V-ATPase B1 subunit decreased markedly within the kidney, despite unchanged transcript levels, suggesting a defect in V-ATPase trafficking or assembly. In addition, morphometric analyses revealed an increased proportion of smaller type A intercalating cells that failed to expand upon acid loading, indicating defective adaptive plasticity. Conclusions: Kidney-specific Wdr72 deletion impairs distal urinary acidification through reduced V-ATPase abundance and apical targeting, altered intercalated cell morphology, and limited adaptive remodeling, resulting in incomplete dRTA. Upregulation of renal ammoniagenesis partially compensates the acidification defect. These findings highlight WDR72 as a key regulator of distal nephron acid–base homeostasis and offer mechanistic insight into WDR72-associated dRTA.
- Open Access
- 21 August 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (11) , 5373-5382
In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease
- 21 August 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (11) , 5373-5382
Open AccessIn vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease
- Open Access
In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder, affecting over 10 million individuals worldwide. Cystic expansion typically progresses to kidney failure and also involves the liver with limited treatment options. Pathogenic variants in PKD1 or PKD2 account for 85-90% of cases. Genetic re-expression of Pkd1 or Pkd2 has been shown to partially reverse key characteristics of the disease phenotype in mice. Despite advancements in the understanding of the genetic basis, it remains unclear whether the correction of underlying pathogenic variants can effectively prevent, modify, or reverse the disease. Additionally, the feasibility of extrinsically delivered genome editing as a treatment option for ADPKD remains largely unexplored. In this study, we employed CRISPR base editing to correct a spectrum of representative pathogenic PKD1 variants selected from a patient cohort achieving precise and efficient editing in vitro . Correction of a representative murine missense variant (c.6646C>T (R2216W)) in primary renal epithelial cells successfully increased polycystin-1 expression and reduced levels of the endoplasmic reticulum stress marker sXBP1. In vivo , base editor delivery to the c.6646C>T (R2216W) knock-in mouse enabled correction of the pathogenic variant, resulting in a significant reduction in liver cysts. These findings provide the first evidence of ADPKD reversibility through genome editing, opening promising novel therapeutic perspectives for affected patients and their families.
Open AccessIn vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder, affecting over 10 million individuals worldwide. Cystic expansion typically progresses to kidney failure and also involves the liver with limited treatment options. Pathogenic variants in PKD1 or PKD2 account for 85-90% of cases. Genetic re-expression of Pkd1 or Pkd2 has been shown to partially reverse key characteristics of the disease phenotype in mice. Despite advancements in the understanding of the genetic basis, it remains unclear whether the correction of underlying pathogenic variants can effectively prevent, modify, or reverse the disease. Additionally, the feasibility of extrinsically delivered genome editing as a treatment option for ADPKD remains largely unexplored. In this study, we employed CRISPR base editing to correct a spectrum of representative pathogenic PKD1 variants selected from a patient cohort achieving precise and efficient editing in vitro . Correction of a representative murine missense variant (c.6646C>T (R2216W)) in primary renal epithelial cells successfully increased polycystin-1 expression and reduced levels of the endoplasmic reticulum stress marker sXBP1. In vivo , base editor delivery to the c.6646C>T (R2216W) knock-in mouse enabled correction of the pathogenic variant, resulting in a significant reduction in liver cysts. These findings provide the first evidence of ADPKD reversibility through genome editing, opening promising novel therapeutic perspectives for affected patients and their families.
- Open Access
- 13 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (10) , 2619-2637
CRISPR-enabled point-of-care genotyping for APOL1 genetic risk assessment
Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensitivity and specificity for point-of-care applications. While these methods have predominantly been used for pathogen sensing, their utilization for genotyping is limited. Here, we report a multiplexed CRISPR-based genotyping assay using LwaCas13a, PsmCas13b, and LbaCas12a, enabling the simultaneous detection of six genotypes. We applied this assay to identify genetic variants in the APOL1 gene prevalent among African Americans, which are associated with an 8–30-fold increase in the risk of developing kidney disease. Machine learning facilitated robust analysis across a multicenter clinical cohort of more than 100 patients, accurately identifying their genotypes. In addition, we optimized the readout using a multi-analyte lateral-flow assay demonstrating the ability for simplified genotype determination of clinical samples. Our CRISPR-based genotyping assay enables cost-effective point-of-care genetic variant detection due to its simplicity, versatility, and fast readout.
- 13 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (10) , 2619-2637
Open AccessCRISPR-enabled point-of-care genotyping for APOL1 genetic risk assessment
Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensitivity and specificity for point-of-care applications. While these methods have predominantly been used for pathogen sensing, their utilization for genotyping is limited. Here, we report a multiplexed CRISPR-based genotyping assay using LwaCas13a, PsmCas13b, and LbaCas12a, enabling the simultaneous detection of six genotypes. We applied this assay to identify genetic variants in the APOL1 gene prevalent among African Americans, which are associated with an 8–30-fold increase in the risk of developing kidney disease. Machine learning facilitated robust analysis across a multicenter clinical cohort of more than 100 patients, accurately identifying their genotypes. In addition, we optimized the readout using a multi-analyte lateral-flow assay demonstrating the ability for simplified genotype determination of clinical samples. Our CRISPR-based genotyping assay enables cost-effective point-of-care genetic variant detection due to its simplicity, versatility, and fast readout.
- Open Access
Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells
Non-viral gene editing via CRISPR-Cas12a offers an alternative to Cas9-based methods, providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high specificity. However, the efficacy of editing outcomes is subject to various factors, with template format playing a crucial role. Currently, the predominant non-viral template format for inducing homology-directed repair (HDR) after nuclease-induced DNA breaks is double-stranded DNA (dsDNA), which is toxic when transfected at high doses. Previous studies have demonstrated that using single-stranded DNA (ssDNA) with flanking double-stranded Cas-target-sequences (CTS) as a repair template for Cas9-mediated gene editing can mitigate this toxicity and increase knock-in efficiency. Here, we investigate CTS design for AsCas12a Ultra by exploring PAM orientation and binding requirements of the Cas12a-crRNA complex. Additionally, we rule out in vitro ssDNase activity of AsCas12a Ultra under cell-physiological Mg 2+ conditions. Finally, we showcase the advantage of using ssDNA with double-stranded CTS end modifications (ssCTS) at high doses for delivering clinically relevant transgenes of varying sizes into three T-cell receptor-CD3 complex genes ( TRAC , CD3 ζ , CD3 ε), achieving up to 90% knock-in rates for a 0.8kb insert at the CD3 ε locus. Overall, AsCas12a Ultra and ssCTS donors represent a platform for highly efficient knock-in in primary human T cells with minimal toxicity.
Open AccessSingle-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells
Non-viral gene editing via CRISPR-Cas12a offers an alternative to Cas9-based methods, providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high specificity. However, the efficacy of editing outcomes is subject to various factors, with template format playing a crucial role. Currently, the predominant non-viral template format for inducing homology-directed repair (HDR) after nuclease-induced DNA breaks is double-stranded DNA (dsDNA), which is toxic when transfected at high doses. Previous studies have demonstrated that using single-stranded DNA (ssDNA) with flanking double-stranded Cas-target-sequences (CTS) as a repair template for Cas9-mediated gene editing can mitigate this toxicity and increase knock-in efficiency. Here, we investigate CTS design for AsCas12a Ultra by exploring PAM orientation and binding requirements of the Cas12a-crRNA complex. Additionally, we rule out in vitro ssDNase activity of AsCas12a Ultra under cell-physiological Mg 2+ conditions. Finally, we showcase the advantage of using ssDNA with double-stranded CTS end modifications (ssCTS) at high doses for delivering clinically relevant transgenes of varying sizes into three T-cell receptor-CD3 complex genes ( TRAC , CD3 ζ , CD3 ε), achieving up to 90% knock-in rates for a 0.8kb insert at the CD3 ε locus. Overall, AsCas12a Ultra and ssCTS donors represent a platform for highly efficient knock-in in primary human T cells with minimal toxicity.
- Open Access
- 1 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (48) , eadg8495
Synthetic genetic circuits to uncover the OCT4 trajectories of successful reprogramming of human fibroblasts
Reprogramming human fibroblasts to induced pluripotent stem cells (iPSCs) is inefficient, with heterogeneity among transcription factor (TF) trajectories driving divergent cell states. Nevertheless, the impact of TF dynamics on reprogramming efficiency remains uncharted. We develop a system that accurately reports OCT4 protein levels in live cells and use it to reveal the trajectories of OCT4 in successful reprogramming. Our system comprises a synthetic genetic circuit that leverages noise to generate a wide range of OCT4 trajectories and a microRNA targeting endogenous OCT4 to set total cellular OCT4 protein levels. By fusing OCT4 to a fluorescent protein, we are able to track OCT4 trajectories with clonal resolution via live-cell imaging. We discover that a supraphysiological, stable OCT4 level is required, but not sufficient, for efficient iPSC colony formation. Our synthetic genetic circuit design and high-throughput live-imaging pipeline are generalizable for investigating TF dynamics for other cell fate programming applications.
- 1 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (48) , eadg8495
Open AccessSynthetic genetic circuits to uncover the OCT4 trajectories of successful reprogramming of human fibroblasts
Reprogramming human fibroblasts to induced pluripotent stem cells (iPSCs) is inefficient, with heterogeneity among transcription factor (TF) trajectories driving divergent cell states. Nevertheless, the impact of TF dynamics on reprogramming efficiency remains uncharted. We develop a system that accurately reports OCT4 protein levels in live cells and use it to reveal the trajectories of OCT4 in successful reprogramming. Our system comprises a synthetic genetic circuit that leverages noise to generate a wide range of OCT4 trajectories and a microRNA targeting endogenous OCT4 to set total cellular OCT4 protein levels. By fusing OCT4 to a fluorescent protein, we are able to track OCT4 trajectories with clonal resolution via live-cell imaging. We discover that a supraphysiological, stable OCT4 level is required, but not sufficient, for efficient iPSC colony formation. Our synthetic genetic circuit design and high-throughput live-imaging pipeline are generalizable for investigating TF dynamics for other cell fate programming applications.
- Top Cited Papers
- 4 August 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (10) , 1120-1126
Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs
CRISPR-based diagnostics enable specific sensing of DNA and RNA biomarkers associated with human diseases. This is achieved through the binding of guide RNAs to a complementary sequence that activates Cas enzymes to cleave reporter molecules. Currently, most CRISPR-based diagnostics rely on target preamplification to reach sufficient sensitivity for clinical applications. This limits quantification capability and adds complexity to the reaction chemistry. Here we show the combination of a CRISPR–Cas-based reaction with a nanozyme-linked immunosorbent assay, which allows for the quantitative and colorimetric readout of Cas13-mediated RNA detection through catalytic metallic nanoparticles at room temperature (CrisprZyme). We demonstrate that CrisprZyme is easily adaptable to a lateral-flow-based readout and different Cas enzymes and enables the sensing of non-coding RNAs including microRNAs, long non-coding RNAs and circular RNAs. We utilize this platform to identify patients with acute myocardial infarction and to monitor cellular differentiation in vitro and in tissue biopsies from prostate cancer patients. We anticipate that CrisprZyme will serve as a universally applicable signal catalyst for CRISPR-based diagnostics, which will expand the spectrum of targets for preamplification-free, quantitative detection.
- 4 August 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (10) , 1120-1126
Top Cited PapersNanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs
CRISPR-based diagnostics enable specific sensing of DNA and RNA biomarkers associated with human diseases. This is achieved through the binding of guide RNAs to a complementary sequence that activates Cas enzymes to cleave reporter molecules. Currently, most CRISPR-based diagnostics rely on target preamplification to reach sufficient sensitivity for clinical applications. This limits quantification capability and adds complexity to the reaction chemistry. Here we show the combination of a CRISPR–Cas-based reaction with a nanozyme-linked immunosorbent assay, which allows for the quantitative and colorimetric readout of Cas13-mediated RNA detection through catalytic metallic nanoparticles at room temperature (CrisprZyme). We demonstrate that CrisprZyme is easily adaptable to a lateral-flow-based readout and different Cas enzymes and enables the sensing of non-coding RNAs including microRNAs, long non-coding RNAs and circular RNAs. We utilize this platform to identify patients with acute myocardial infarction and to monitor cellular differentiation in vitro and in tissue biopsies from prostate cancer patients. We anticipate that CrisprZyme will serve as a universally applicable signal catalyst for CRISPR-based diagnostics, which will expand the spectrum of targets for preamplification-free, quantitative detection.